S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Options Trading Plan–Perfect For Beginners (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Options Trading Plan–Perfect For Beginners (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Options Trading Plan–Perfect For Beginners (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Options Trading Plan–Perfect For Beginners (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
52-week Low Names To Tip The Upside Scale In Your Favor
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
Analysts Went All In On These Computer Stocks, Save Your Spot
Things to know about California's new proposed rules for insurance companies
WARNING: Seven millionaires to trigger sudden market panic? (Ad)
KB Home Price Weakness is a Signal to Buy this Cash Machine
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023

Rocket Pharmaceuticals (RCKT) Stock Forecast, Price & News

$20.40
-0.44 (-2.11%)
(As of 09/22/2023 ET)
Compare
Today's Range
$20.13
$21.16
50-Day Range
$15.07
$24.05
52-Week Range
$11.78
$24.65
Volume
847,180 shs
Average Volume
2.24 million shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.45

Rocket Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
142.4% Upside
$49.45 Price Target
Short Interest
Bearish
8.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.46mentions of Rocket Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$108,381 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.15) to ($2.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

143rd out of 968 stocks

Pharmaceutical Preparations Industry

43rd out of 442 stocks


RCKT stock logo

About Rocket Pharmaceuticals (NASDAQ:RCKT) Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

RCKT Price History

RCKT Stock News Headlines

MarketBeat's Top 5 Stock Picks - Just Released
MarketBeat has just released five new trading ideas to All Access subscribers, but Tesla, Apple, and Netflix didn't make the cut. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. Now, MarketBeat thinks these five stocks may be even better buys.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Rocket Pharmaceuticals stock takes flight on FDA agreement
Why Is Rocket Pharmaceuticals (RCKT) Stock Up 35% Today?
Analyst Expectations for Rocket Pharmaceuticals's Future
See More Headlines
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RCKT Company Calendar

Last Earnings
8/10/2023
Today
9/23/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RCKT
Employees
240
Year Founded
2018

Price Target and Rating

Average Stock Price Forecast
$49.45
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+142.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$-221,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.47 per share

Miscellaneous

Free Float
55,482,000
Market Cap
$1.64 billion
Optionable
Optionable
Beta
1.16

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Gaurav D. Shah M.D. (Age 48)
    CEO & Director
    Comp: $1.05M
  • Ms. Kinnari Patel M.B.A. (Age 44)
    MBA, Pharm.D., PharmD, Pres & COO
    Comp: $849.93k
  • Mr. John C. Militello CPA (Age 50)
    CPA, VP, Sr. Controller, Treasurer, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $501.42k
  • Mr. Mayo Pujols (Age 54)
    Chief Technical Officer & Exec. VP
    Comp: $649.71k
  • Mr. Raj Prabhakar M.B.A. (Age 49)
    Sr. VP & Chief Bus. Officer
    Comp: $619.13k
  • Mr. Martin Louis Wilson J.D. (Age 47)
    Gen. Counsel, Chief Compliance Officer & Sr. VP
  • Kevin Giordano
    Director of Corp. Communications
  • Ms. Isabel Carmona J.D.
    Sr. VP & Chief HR Officer
  • Mr. Jonathan Schwartz M.D. (Age 58)
    Chief Gene Therapy Officer & Sr. VP of Clinical Devel.
  • Dr. Gayatri R. Rao J.D.
    M.D., Chief Devel. Officer of LVV & Sr. VP













RCKT Stock - Frequently Asked Questions

Should I buy or sell Rocket Pharmaceuticals stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings
or view top-rated stocks.

What is Rocket Pharmaceuticals' stock price forecast for 2023?

12 brokers have issued 1 year price targets for Rocket Pharmaceuticals' shares. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they expect the company's share price to reach $49.45 in the next year. This suggests a possible upside of 142.4% from the stock's current price.
View analysts price targets for RCKT
or view top-rated stocks among Wall Street analysts.

How have RCKT shares performed in 2023?

Rocket Pharmaceuticals' stock was trading at $19.57 at the start of the year. Since then, RCKT stock has increased by 4.2% and is now trading at $20.40.
View the best growth stocks for 2023 here
.

When is Rocket Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our RCKT earnings forecast
.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its quarterly earnings results on Thursday, August, 10th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.01. During the same period in the prior year, the company earned ($0.83) earnings per share.

What ETFs hold Rocket Pharmaceuticals' stock?
What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.38%), State Street Corp (3.95%), Goldman Sachs Group Inc. (1.79%), Dimensional Fund Advisors LP (1.66%), Geode Capital Management LLC (1.47%) and Perceptive Advisors LLC (1.45%). Insiders that own company stock include Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends
.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $20.40.

How much money does Rocket Pharmaceuticals make?

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.64 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.34) on an earnings per share basis.

How many employees does Rocket Pharmaceuticals have?

The company employs 240 workers across the globe.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.

This page (NASDAQ:RCKT) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -